Major Shareholder Yun Yao's Stake Diluted to 31.51% Following Recent Private Placement
INDP has more than doubled off its 52-week low of $0.92 on light trading volume (0.1× avg).
Summary
Major shareholder Yun Yao's stake in Indaptus Therapeutics has been diluted to 31.51% following the company's recent $12 million private placement, without any sale of shares by Ms. Yao.
Key Events · Ownership and Investor Activity · INDP
-
Shareholder Stake Diluted
Yun Yao's beneficial ownership decreased from 35.7% to 31.51% of outstanding common stock.
-
Passive Reduction
The reduction in percentage ownership is due to the company's recent $12 million private placement, which increased the total number of outstanding shares, not from any sale by Ms. Yao.
-
Impact of Capital Raise
This filing reflects the dilutive effect of the company's recent financing activities on its major investors, following the 8-K filed on June 24, 2026, which disclosed the private placement.
Analysis · INDP · Life Sciences
This amendment to Schedule 13D reports that Yun Yao's beneficial ownership in Indaptus Therapeutics has decreased from 35.7% to 31.51%. This reduction is solely due to the increase in outstanding common shares from the company's recent $12 million private placement on June 24, 2026, not from any sale by Ms. Yao. This highlights the dilutive impact of the company's capital raising activities on its major shareholders.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDP was trading at $3.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $386.2M. The 52-week trading range was $0.92 to $13.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.